Theratechnologies Examines EVAF's Role in CVD Risk for HIV Patients
Impact of Excess Visceral Abdominal Fat on Cardiovascular Disease
MONTREAL — Theratechnologies Inc. (“Theratechnologies” or the “Company”) (NASDAQ: THTX), a biopharmaceutical company engaged in the development and commercialization of innovative therapies, recently announced significant findings from two poster presentations that highlight the relationship between excess visceral abdominal fat (EVAF) and cardiovascular disease (CVD) risk in people with HIV (PWH).
Findings from IDWeek 2024
At IDWeek 2024, it was revealed that EVAF is a crucial risk factor contributing to increased CVD risk in PWH undergoing modern anti-retroviral therapy (ART). Investigators from the Visceral Adiposity Measurement and Observations Study (VAMOS) presented compelling data that connected EVAF to elevated cardiovascular risks, spotlighting the need for targeted interventions.
Dr. Christian Marsolais, Senior Vice President and Chief Medical Officer of Theratechnologies, emphasized the importance of recognizing EVAF as a significant risk factor. He shared, "These studies reveal that understanding and tackling excess visceral fat can significantly enhance outcomes for those living with HIV who are receiving ART medicines."
Understanding the VAMOS Study
The VAMOS study is the first of its kind aimed at exploring the implications of EVAF in relation to cardiovascular health among PWH on modern ART regimens. This observational study analyzed 170 participants, shedding light on the prevalence of EVAF, which stood at 58%, with an average visceral fat area measured at 148 cm2.
Key Observations from VAMOS Data
Among those with EVAF, significant levels of homeostatic model assessment for insulin resistance (HOMA-IR) and triglyceride-to-high-density lipoprotein (TG:HDL) ratios were noted. The study found a strong correlation between growing visceral fat and increased insulin resistance, indicating that managing EVAF could be vital in reducing cardiovascular risks.
Moreover, the study established that elevated EVAF was linked to a higher risk of atherosclerotic cardiovascular disease (ASCVD) over a decade, demonstrating the profound impact of metabolic health on long-term cardiovascular outcomes.
Exploring Tesamorelin's Effects
Additionally, researchers focused on the role of tesamorelin, a growth hormone-releasing factor (GHRF), in combating EVAF. The analysis from two phase 3 randomized trials revealed promising results in minimizing CVD risks associated with high levels of visceral fat.
Results from Clinical Trials
A trial encompassing 543 PWH examined the change in 10-year ASCVD risk scores before and after 26 weeks of tesamorelin treatment. Although most participants presented with low CVD risks initially, nearly half showed borderline to high risk, underscoring the significance of monitoring cardiovascular health in this demographic.
Through this treatment, participants experienced a modest yet notable reduction in ASCVD risk scores, especially among those who began with higher risks. The findings suggest that tesamorelin's ability to lower total cholesterol presents a potential pathway for improving cardiovascular health in individuals with HIV.
The Importance of IDWeek 2024
Held from October 16 to 19, IDWeek 2024 represented a vital convergence of leading health organizations, amplifying discussions about key topics impacting healthcare, including the interplay of diabetes, liver health, and cardiovascular diseases in the HIV population.
About Theratechnologies
As a dedicated biopharmaceutical entity, Theratechnologies (NASDAQ: THTX) focuses on addressing unmet medical needs through the development of innovative therapies. Further information about their research and products can be found on Theratechnologies' official website and through their public filings.
Frequently Asked Questions
What is the significance of the VAMOS study?
The VAMOS study is pivotal in establishing a link between excess visceral abdominal fat and heightened cardiovascular disease risk in people living with HIV.
How does tesamorelin affect cardiovascular disease risk?
Tesamorelin has shown potential to reduce cardiovascular disease risk by lessening excess visceral abdominal fat in individuals at higher risk.
What was presented at IDWeek 2024 regarding EVAF?
Researchers presented findings indicating that excess visceral abdominal fat is an overlooked risk factor for cardiovascular disease among people living with HIV.
How prevalent is excess visceral abdominal fat in people with HIV?
In the VAMOS study, the prevalence of excess visceral abdominal fat was found to be 58% among the participants.
Why is it important to address EVAF in HIV patients?
Addressing EVAF is crucial as it significantly correlates with increased risks for cardiovascular disease and other metabolic issues, particularly in aging individuals with HIV.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- Challenges Faced by Russian Stocks as MOEX Sees Declines
- Colombia Stock Market Sees Positive Gains with COLCAP Rise
- Mexico Stock Market Update: S&P/BMV IPC Sees Minor Decline
- EVERTEC Announces Consistent Quarterly Dividend for Shareholders
- Telix Pharmaceuticals Moves Forward with Nasdaq Listing Plans
- Monroe Federal Bancorp, Inc. Readies for Significant IPO Event
- GPM Initiates Investigation into CSX Corporation's Practices
- Understanding the Upcoming iShares iBonds ETF Liquidations
- Investigation Launched into CSX Corporation for Investor Protection
- Baylin Technologies Enhances Connectivity with New Antennas
Recent Articles
- PTL Limited Achieves Milestone with Successful IPO Completion
- Verizon Set to Reveal Third Quarter Earnings Soon
- ADT Inc. Announces Upcoming Third Quarter Results Event
- Hudbay Minerals Inc. to Announce Q3 2024 Financial Results
- Greenheart Gold Completes C$36 Million Private Placement Offering
- Picton Mahoney Asset Management Declares October Distributions
- Understanding the P/E Ratio for Avantor Inc. Stocks Today
- MolinaCares Accord Supports Community Health Initiatives
- Three Stocks with Momentum Ahead of the Upcoming Elections
- Stock Market Updates: Gains, Losses, and Oil Inventory Trends
- Coca-Cola Welcomes Netflix's Bela Bajaria to Its Board Team
- Discover the Impressive Returns from Ecolab Stock Over 20 Years
- Alcoa's Strategy for Growth Depends on Kwinana and San Ciprian
- Exploring Johnson & Johnson's Path to Market Leadership in 2025
- Unlocking the Potential of Carpenter Technology Stock Today
- 5WPR Earns Recognition as Data Innovation Leader in 2024
- Investors Urged to Pursue DexCom, Inc. Class Action Lawsuit
- Reunion's Q3 Analysis Highlights Surge in Clean Energy Credits
- Tomorrow Health Welcomes New Leaders to Strengthen Its Mission
- Understanding Medicare Open Enrollment: Key Insights for All
- California Dairy Farms Struggle As Bird Flu Hits Hard
- MasterBrand Cabinets Reaches Record Stock Price of $19.11
- Iron Mountain Reaches New Heights with Record Stock Surge
- New Heights for NYMTM Stock: Insights on Recent Growth
- FCC Proposes $147K Fine Against ESPN Over Alert Tone Violations
- Daniel Loeb Adjusts Hedge Fund for Republican Election Impact
- NuZee Stock Surges on Major Operational Changes and Leadership Shift
- Investors Encouraged to Join STMicroelectronics Class Action
- Ascend Wellness Unveils Innovative THC-Cannabinoid Edibles
- Stanley Druckenmiller Notes Bitcoin Surge Amid Trump Speculations
- Meta's Controversial AI Claims and OSI's Call for Clarity
- Canadian General Investments, Limited Announces New Dividend
- Transforming THE LOT Comic into a Captivating Horror Film
- Ulta Beauty's Future: Transitional Challenges Ahead for FY25
- Domino's Pizza Faces Class Action Amid Investment Losses
- Alnylam Pharmaceuticals Advances Cardiomyopathy Treatment Efforts
- Legal Action Alert: Orthofix Medical Faces Class Action Suit
- Canadian General Investments Increases Shareholder Dividend Value
- Class Action Lawsuit Filed Against Elanco Animal Health Inc.
- Understanding Market Sentiments for Enphase Energy Investments
- TownePlace Suites London Welcomes Guests with Renovated Spaces
- Rayonier Advanced Materials Faces Legal Inquiry Post Incident
- Wise Investors Take Notice of Western Digital Options Trends
- Tour24 Secures Funding from Mirasol Capital to Innovate Growth
- Class Action Filed Against EngageSmart Inc. by Pomerantz LLP
- Critical Updates on Terran Orbital Corporation for Investors
- Insight into SoFi Techs Options Trading Trends and Strategies
- AMEX Assurance Company Receives Stable Credit Ratings from AM Best
- Class Action Lawsuit Filed Against DexCom, Inc. for Securities Fraud
- Realty Income's Strategic Approach: Dividends and Growth Explained